NCT06134622

Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 832 (actual)
• Sponsor: The First Affiliated Hospital of University of Science and Technology of China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy and safety of tirofiban administration after intravenous thrombolysis for patients with AIS.

Detailed description

The standard treatment for acute ischemic stroke is intravenous thrombolysis to dissolve fibrin and restore blood flow. However, reocclusion of blood vessels and stroke progression remain challenges after this treatment.

Conditions

• Acute Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Intravenous thrombolysis plus tirofiban	Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.
DRUG	Intravenous thrombolysis plus placebo	placebo (saline)

Timeline

• Start date: 2024-03-14
• Primary completion: 2024-09-25
• Completion: 2024-12-30
• First posted: 2023-11-18
• Last updated: 2025-05-04

Locations

1 site across 1 country: China